JSR Life Sciences Launches 'Similis Bio' to Help Partners Accelerate Biosimilar Development
10.5.2022 15:00:00 EEST | Business Wire | Press release
JSR Life Sciences, LLC (JSR) today announced the launch of a new business division, Similis Bio (Similis), which will operate a partnering program designed to help biopharmaceutical companies improve the efficiency and cost of biosimilar development. Similis will rely on core expertise in developing and manufacturing biologics to mitigate the challenges inherent in biosimilar drug development.
Similis provides biosimilar drug developers with solutions designed to accelerate development timelines and lower costs. By offering complete analytical and process development packages, Similis supplies companies with data to determine an appropriate biosimilar target, accelerate early program development, and reduce analytical costs. Data packages include reference product data, analytical procedures, process expertise, and CMC templates from a centralized model designed to give partners access to higher quality biosimilar packages at a lower cost than other development models.
Additionally, Similis will establish co-development agreements with partner companies to start the development of multiple biosimilar programs in parallel, giving partners an exclusive right, but not an obligation, to purchase multiple programs. JSR designed this collaboration model to reduce the risk from program cancellations and extend market analysis timelines.
“This model will enable changes in strategy far beyond traditional drug development approaches by centralizing reference product data and expertise under one roof,” said JSR Life Sciences’ Chief Technology Officer Jean-Pierre Wery. “Similis brings the broad expertise of JSR Life Sciences companies together to jump-start the development of promising biosimilars. By improving timelines and development costs for drug makers, more biosimilars can be brought to market faster. Ultimately, that means more choice and lower costs for patients.”
Biosimilars—the generic form of FDA-approved biologics—are derived from living organisms, making them inherently complex. Unlike small-molecule generic drugs, biosimilars cannot fully replicate their brand-name counterparts, so an array of analytical data must be collected to ensure they sufficiently reflect biosimilarity to the FDA-approved reference products to which they are being compared. This process requires costly and significant investment in expertise, state-of-the-art technology, and extensive data gathering, including rigorous clinical trials to ensure a biosimilar's safety and efficacy. JSR launched Similis Bio to mitigate these barriers to market entry and promote more productive development programs.
For more information about Similis Bio visit: JSRLifeSciences.com/similis.
About JSR Life Sciences, LLC
A business unit of JSR Corporation, JSR Life Sciences, LLC is changing human health as a strategic partner and pathfinder for the life sciences industry. Rooted in a history of materials innovation, JSR Life Sciences provides specialized products, materials, and services to biopharmaceutical companies and academic researchers. Together with its world-class affiliates, JSR Life Sciences offers best-in-class integrated services that de-risk molecule selection, accelerate biologic development timelines, increase clinical success rates, and develop novel in vitro diagnostics. JSR Life Sciences’ global network of affiliates includes Crown Bioscience, KBI Biopharma, Inc., Selexis SA, and MEDICAL & BIOLOGICAL LABORATORIES CO., LTD. The company operates R&D and applications labs, manufacturing facilities, and sales offices worldwide. For more information, visit JSRLifeSciences.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220510005401/en/
Contact information
Missy Bindseil
JSR Life Sciences Company Inquiries
Director, Marketing & Communications
mbindseil@jsr-nahq.com
Mike Beyer
JSR Life Sciences Media Inquiries
Sam Brown Inc.
mikebeyer@sambrown.com
+1 312-961-2502
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Canva Brings On-Brand Designs Directly into AI Assistants6.2.2026 01:00:00 EET | Press release
The future of work is being rewritten by AI, with professionals accomplishing in minutes what used to take hours. But there's been one persistent breaking point in AI assistants: generic visual outputs and off-brand colors that undermine AI speed with tedious manual cleanup. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260205384226/en/ Canva Today, that friction ends as Canva brings brand intelligence directly into the AI tools where modern day work happens most. Starting now, ChatGPT users can create designs completely tied to their Canva Brand Kit, making a company’s brand come to life visually and function as a living participant in AI workflows. This expansion marks the coming together of Canva and ChatGPT, two category-defining platforms, in a new way to make on-brand design more accessible and fluid. From client-ready pitch decks to social posts and professional-looking posters, the partnership continues to fuel Canv
DNIB.com Reports Internet Has 386.9 Million Domain Name Registrations at the End of the Fourth Quarter of 20256.2.2026 00:04:00 EET | Press release
VeriSign, Inc. (NASDAQ: VRSN), a global provider of critical internet infrastructure and domain name registry services, today announced that, according to the latest Domain Name Industry Brief Quarterly Report from DNIB.com, the fourth quarter of 2025 closed with 386.9 million domain name registrations across all top-level domains (TLDs), an increase of 8.4 million domain name registrations, or 2.2% compared to the third quarter of 2025. Domain name registrations also increased by 22.7 million, or 6.2%, year over year. The .com and .net TLDs had a combined total of 173.5 million domain name registrations in the domain name base at the end of the fourth quarter of 2025, an increase of 1.6 million domain name registrations, or 0.9% compared to the third quarter of 2025. The .com and .net TLDs had a combined increase of 4.5 million domain name registrations, or 2.6%, year over year. As of Dec. 31, 2025, the .com domain name base totaled 161.0 million domain name registrations and the .net
Calix CEO Michael Weening To Keynote at MWC26 Barcelona: How Agentic AI Enables an ‘Experience of One’ for Every Subscriber5.2.2026 21:30:00 EET | Press release
Calix, Inc. (NYSE: CALX) today announced that President and Chief Executive Officer Michael Weening will deliver a keynote in the Tuesday morning, March 3, “Architects of the AI Age” session at MWC26 Barcelona. Calix’s presence at MWC, the world’s largest and most influential connectivity event, extends the momentum following the recent launch of the company’s AI‑native platform. Weening will take the MWC Main Stage on Tuesday morning to reveal a transformative vision for telecommunications: how agentic AI enables service providers to deliver an “experience of one” to millions of subscribers simultaneously—personalizing every interaction in real time, unlocking new revenue streams, and fundamentally redefining what it means to grow in the connected world. He will be joined onstage by leading AI researcher and author Kate Crawford, a globally recognized voice in AI ethics, to explore how this transformation goes beyond automation. They will address how responsible agentic AI can amplify
Verimatrix: Sale of Extended Threat Defense Assets (Mobile Application Protection) to Guardsquare5.2.2026 18:45:00 EET | Press release
Regulatory News: Verimatrix, (Euronext Paris: VMX), a leading provider of security solutions for a safer connected world, today announced that it has completed the sale of 100% of its Extended Threat Defense (XTD) assets to Guardsquare, a Belgian company and leader in mobile application security. This transaction follows the signing of an agreement announced in a press release on December 8, 2025, as well as regulatory approval. It is part of Verimatrix's overall strategy to refocus on its core business, reflecting the group's strategic decision to concentrate on the key growth segments of the video protection market. Commenting on the announcement, Laurent Dechaux, CEO of Verimatrix, said: “Verimatrix has a strong technological foundation that enables our teams to pursue new business opportunities. Our priorities are to identify key growth drivers, address our clients’ needs effectively, and optimize resource allocation. I look forward to presenting these strategic initiatives to the
Andersen Consulting Enters Into Collaboration Agreement With Alfa Group5.2.2026 16:30:00 EET | Press release
Andersen Consulting adds depth to its cybersecurity offering with collaborating firm Alfa Group, a leading technology firm with nearly three decades of experience helping organizations safeguard and optimize their operations. Founded in 1996 and headquartered in Rome, Alfa Group delivers advanced solutions in cybersecurity, fraud detection and prevention, incident response, and vulnerability management, as well as select business process management services. Its proprietary technology, N.O.V.A., is an end-to-end managed service that integrates Alfa Group’s innovations with third-party systems to safeguard digital infrastructures, mitigate risk, and enhance operational efficiency. The firm serves clients across industries including finance and insurance, defense and aerospace, telecom, manufacturing, energy, and pharmaceutical. "Our collaboration with Andersen Consulting allows us to extend our reach and deliver greater value to clients navigating the complexities of digital transformat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom